mybet Holding SE

  • WKN: A2LQ00
  • ISIN: DE000A2LQ009
  • Land: Deutschland

Nachricht vom 01.10.2018 | 15:35

mybet Holding SE: Opening of insolvency proceedings

mybet Holding SE / Key word(s): Insolvency
mybet Holding SE: Opening of insolvency proceedings

01-Oct-2018 / 15:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


mybet Holding SE: Opening of insolvency proceedings

Berlin, 1 October 2018 - The local court of Charlottenburg (Berlin) has just opened insolvency proceedings (36m IN 4011/18) on the assets of mybet Holding SE (ISIN DE000A2LQ009, new shares: ISIN DE000A2LQ7F4, convertible bond 2015/2020: DE000A1X3GJ8 and 2017/2020: DE000A2G8472). Furthermore, the local court of Charlottenburg (Berlin) has just opened insolvency proceedings on the assets of ANYBET GmbH and on the assets of SWS Service GmbH, both subsidiaries of mybet Holding SE. Attorney at Law, Sascha Feies, Berlin, has each been appointed as insolvency administrator on the assets of mybet Holding SE and on the assets of the aforementioned subsidiaries.


Information and Explanation of the Issuer to this News:

Reporting company:
mybet Holding SE, ISIN DE000A2LQ009, new shares: ISIN DE000A2LQ7F4, in the Prime Standard segment of the Frankfurt Stock Exchange

Reporting Person:
Markus Peuler, member of the management board
 

Contact:
mybet Holding SE
Karl-Liebknecht-Straße 32
D-10178 Berlin
Investor & Public Relations
tel +49 30 22 90 83-161
fax +49 30 22 90 83-150
E-Mail: ir@mybet.com


01-Oct-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021